Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
France Targets Shein, Temu With Fast-Fashion Fees 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Shein Shares Slide 9% in Hong Kong IPO Debut 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Nears Astra AI Model Launch With Safety Focus 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
CAMBRIDGE, Mass., March 13, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 17th Annual Needham Healthcare Conference in New York, New York on Wednesday, March 28, 2018 at 9:00am Eastern Time.
The presentation will be live webcast at: http://wsw.com/webcast/needham86/vcel, and may be accessed from the news and events section of the Vericel website.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
(vcel-corp)
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
